$REPL Gains Momentum with Analyst Upgrades and FDA Fast Trac$REPL received 3 analyst upgrades, all raising their price target to $17-18. That’s what happens when you get into the accelerated FDA approval process. Also keeping tabs on MYNZ—it’s being talked about as a stock with explosive potential.